

## What is claimed:

(1) A method treating and/or preventing allergic and inflammatory conditions of the skin or airway passages in a human of 12 years and older in need of such treating and /or preventing which comprises administering an effective amount of desloratedine for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratedine in the range of about 2.90 ng/mL to about 4.54 ng/mL,or an arithmetic mean steady state maximum plasma concentration of desloratedine in the range of about 3.2 ng/mL to about 5.0 ng/mL.

10

15

20

5

(2) The method of claim 1 wherein the geometric mean  $T_{max}$  is in the range of about 1.60 to about 2.50 hours.

(3) The method of claim 1 wherein the arithmetic mean  $T_{max}$  is in the range of about 2.54 to about 3.96 hours.

A method treating and/or preventing allergic and inflammatory conditions of the skin or airway passages in a human of 12 years and older in need of such treating and /or preventing which comprises administering an effective amount of desloratedine for a time sufficient to produce a geometric mean steady state maximum plasma concentration of 3-OH-desloratedine in the range of about 1.50 ng/mL to about 2.34 ng/mL, or an arithmetic mean steady state maximum plasma concentration of 3-OH-desloratedine in the range of about 1.60 ng/mL to about 2.50 ng/mL.

618/03/

(5) The method of claim 4 wherein the geometric mean  $T_{max}$  is in the range of about 4.00 to about 6.25 hours.



- The method of claim 4 wherein the arithmetic mean  $T_{\text{max}}$  is in the range of (6) about 3.80 to about 5\95 hours.
- The method of claim 4 wherein the amount of desloratadine is about 5.0 (7) mg/day, in single or divided doses.
- 5 The method of claim 1 wherein the amount of desloratadine is about 5.0 (8)mg/day, in single or divided doses.
  - The method of claim 1 wherein the amount of desloratadine is about 5 (9)mg/day.
  - The method of claim 1/wijerein the amount of desloratadine is about 2.5 mg/ twice a day.

ļ. L THE STATE 10

The method of claim 1 wherein the geometric mean AUC(0-24hr) for (11)desloratadine is in the range of about 39.5 ng.hr/mL to about 61.8 ng.hr/mL.

The method of claim 1 wherein the arithmetic mean AUC(0-24hr) for (12)desloratadine is in the range of about 45.5 ng.hr/mL to about 71.1 ng.hr/mL.

15 The method of claim 4 wherein the geometric mean AUC(0-24hr) for 3-OH-(13)desloratadine is in the range of about 24.3 ng.hr/mL to about 38.0 ng.hr/mL.

The method of claim 4 wherein the arithmetic mean AUC(0-24hr) for 3-OHdesloratadine is in the range of about 25,8 ng.hr/mL to about 40.4 ng.hr/mL.

The method of claim 1 wherein the allergic reaction is seasonal allergic rhinitis, pernninal allergic rhinitis, atopic dermatitis, urticaria or allergic asthma.

A method of treating and/or preventing seasonal or perennial allergic rhinitis in a human of 12 years and older which comprises administering an effective amount of desloratadine for a time sufficient to produce a geometric

mean steady state maximum plasma concentration of desloratadine in the range



of about 2.90 ng/mL to about 4.54 ng/mL,or a arithmetic mean steady state maximum plasma concentration of desloratedine in the range of about 3.2 ng/mL to about 5.0 ng/mL.


- (17) The method of claim 16 wherein the geometric mean T<sub>max</sub> is in the range of about 1.60 to about 2.50 hours.
- (18) The method of claim 16 wherein the arithmetic mean  $T_{max}$  is in the range of about 2.54 to about 3.96 hours.
- A method of treating and/or preventing seasonal or perennial allergic rhinitis in a human of 12 years and older which comprises administering an effective amount of 3-OH-desloratadine for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 1.50 ng/mL to about 2.34 ng/mL,or a arithmetic mean steady state maximum plasma concentration of 3-OH-desloratadine in the range of about 1.60 ng/mL to about 2.50 ng/mL.
- (20) The method of claim 19 wherein the geometric mean T<sub>max</sub> is in the range of about 4.00 to about 6.25 hours.
- (21) The method of claim 19 wherein a arithmetic mean steady state maximum plasma concentration of 3/OH-desloratadine in the range of about 1.60 ng/mL to about 2.50 ng/mL is produced
- (22) The method of claim 19 wherein the arithmetic mean  $T_{\text{max}}$  is in the range of about 3.80 to about 5.95 hours.
- (23) The method of claim 19 wherein the amount of desloratedine is about 5.0 mg/day, in single or divided doses.

10

15

308/





- The method of claim 16 wherein the amount of deslorated ine is about 5 mg/day.
- The method of claim 16 wherein the amount of desloratadine is about 2.5 5 (26)mg/ twice a day.
  - (27) The method of claim 16 wherein the geometric mean AUC(0-24hr) for desloratedine is in the range of about 39.5 ng.hr/mL to about 61.8 ng.hr/mL.
  - The method of claim 16 wherein the arithmetic mean AUC(0-24hr) for (28)desloratedine is in the range of about 45.5 ng.hr/mL to about 71.1 ng.hr/mL.
  - (29)The method of claim 19 wherein the geometric mean AUC(0-24hr) for 3-OH-desloratedine is in the range of about 24.3 ng.hr/mL to about 38.0 ng.hr/mL.
  - The method of claim 19 wherein the arithmetic mean AUC(0-24hr) for 3-(30)OH-desloratedine is in the range of about 25.8 ng.hr/mL to about 40.4 ng.hr/mL.
- (31) A method of treating and/or preventing atopic dermatitis or urticaria in a 15 human of 12 years and older in need of such which comprises administering an effective amount of desloratadine for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL,or a arithmetic mean steady state 20 maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL.
  - The method of claim 31 wherein the geometric mean T<sub>max</sub> is in the range of (32)about 1.60 to about 2.50 hours.



(33) The method of claim 31 wherein the arithmetic mean  $T_{\text{max}}$  is in the range of about 2.54 to about 3.96 hours.

(34) A method of treating and/or preventing atopic dermatitis or urticaria in a human of 12 years and older in need of such which comprises administering an effective amount of desloratedine for a time sufficient to produce a geometric mean steady state maximum plasma concentration of 3 OH-desloratedine in the range of about 1.50 ng/mL to about 2.34 ng/mL,or a arithmetic mean steady state maximum plasma concentration of desloratedine in the range of about 1.6 ng/mL to about 2.50 ng/mL.

10 (35) The method of claim 34 wherein the geometric mean T<sub>max</sub> of 3 OH-desloratedine is in the range of about 4.00 to about 6.25 hours.

- (36) The method of claim 34 wherein the arithmetic mean T<sub>max</sub> of 3 OH-desloratedine is in the range of about 3.80 to about 5.95 hours.
- (37) The method of claim 34 wherein the amount of desloratadine is about 5.0 mg/day, in single or divided doses.
- (38) The method of claim 31 wherein the amount of desloratedine is about 5.0 mg/day, in single or divided doses.
- (39) The method of claim 31 wherein the amount of desloratadine is about 5 mg/day.
- 20 (40) The method of claim 31 wherein the amount of desloratadine is about 2.5 mg/ twice a day
  - (41) The method of claim 31 wherein the geometric mean AUC(0-24hr) for desloratedine is in the range of about 39.5 ng.hr/mL to about 61.8 ng.hr/mL.


The state case was the first of the state state than the fact that the f

15

171

15






- (43) The method of claim 34 wherein the geometric mean AUC(0-24hr) for 3-OH-desloratedine is in the range of about 24.3 ng.hr/mL to about 38.0 ng.hr/mL.
- (44) The method of claim 34 wherein the arithmetic mean AUC(0-24hr) for 3-OH-desloratedine is in the range of about 25.8 ng.hr/mL to about 40.4 ng.hr/mL.
- A method of treating and/or preventing the nasal and non-nasal symptoms of seasonal and perennial allergic rhinitis and for treating chronic idiopathic urticaria in a human of 12 years and older in need of such treating and /or preventing which comprises administering to said human about 5.0 mg of desloratedine once a day for about 10 days to produce at an arithmetic mean time to maximum plasma concentration (T<sub>max</sub>) of about 3 hours post dose, an arithmetic mean steady state maximum plasma concentration(C<sub>max</sub>) of desloratedine of about 4 ng/mL, and an area under the concentration-time curve of 56.9ng.hr/mL of desloratedine.
- (46) The method of claim 45 wherein the arithmetic mean steady state maximum plasma concentration( $C_{max}$ ) of 3-OH-desloratedine produced post dose at an arithmetic mean time to maximum plasma concentration ( $T_{max}$ ) of about 4.8 hours, is about 2 ng/mL, and an area under the concentration-time curve of desloratedine is about 32.3 ng.hr/mL.
- (47) The method of claim 46 wherein the arithmetic mean AUC(0-24hr) for 3-OH-desloratedine is in the range of about 25.8 ng.hr/mL to about 40.4 ng.hr/mL.

  (48) A method of treating and/or preventing the nasal and non-nasal symptoms of seasonal and perennial allergic rhinitis and/or of treating chronic idiopathic

SUB Oa)



10

15


urticaria in a human of 12 years and older in need of such treating and /or preventing which comprises administering an effective amount of desloratadine for a time sufficient to produce a steady state geometric mean plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or a steady state arithmetid mean maximum plasma concentration of desloratadine in the range of about 3.2 hg/mL to about 5.0 ng/mL.

- The method of claim 48 wherein the arithmetic mean steady state (49)maximum plasma concentration(C<sub>max</sub>) of 3-OH-desloratadine produced post dose at arithmetic mean time to maximum plasma concentration (T<sub>max</sub>) in the range of about 3.80 hours to 5.95 hours, is in the range about 1.60 ng/mL to about 2.50 ng/mL, and an area under the concentration-time curve of desloratadine was in the range of about 25.8 ng.hr/mL to about 40.4 ng.hr/mL.
- The method of claim 48 wherein the amount of desloratadine is about 2.5 mg/twice a day.
- The method of claim 48 wherein the amount of desloratedine is about 5 mg/day.

(52) A method of treating and/or preventing the nasal and non-nasal symptoms of seasonal and perennial allergic rhinitis and/or of treating chronic idiopathic urticaria in a human of 12 years and older in need of such treating and /or preventing which comprises administering to said human about 5.0 mg of desloratadine once a day for about 10 days to produce an arithmetic mean steady state maximum plasma concentration (C<sub>max</sub>) of desloratadine at an arithmetic

mean time to maximum plasma concentration (T<sub>max</sub>) of about 3 hours post dose.

5



A method of treating and/or preventing the nasal and non-nasal symptoms of seasonal and perennial allergic rhinitis and/or of treating chronic idiopathic urticaria in a human of 12 years and older in need of such treating and /or preventing which comprises administering to said human about 5.0 mg of desloratedine once a day for about 10 days to produce at an arithmetic mean time to maximum plasma concentration (T<sub>max</sub>) of about 3 hours post dose, an arithmetic mean steady state maximum plasma concentration (C<sub>max</sub>) of desloratedine of about 4 ng/mL, and an area under the concentration-time curve of 56.9 ng.hr/mL of desloratedine.

- (55) The method of claim 54 wherein the arithmetic mean steady state maximum plasma concentration(C<sub>max</sub>) of 3-OH-desloratedine produced at arithmetic mean time to maximum plasma concentration (T<sub>max</sub>) of about 4.8 hours post dose, is about 2.0 ng/mL, and an area under the concentration-time curve of desloratedine is about 32.3 ng.hr/mL.
- 20 (56) A method of treating chronic idiopathic urticaria in a human of 12 years and older in need of such treating and /or preventing which comprises administering to said human about 5.0 mg of desloratedine once a day for about 10 days to produce at an arithmetic mean time to maximum plasma concentration (T<sub>max</sub>) of about 3 hours post dose, an arithmetic mean steady state maximum plasma

12423\_1

10

15

20



concentration (C<sub>max</sub>) of desloratadine of about 4 ng/mL, and an area under the concentration-time curve of 56.9 ng.hr/mL of desloratadine.

- (57) The method of claim 56 wherein the arithmetic mean steady state maximum plasma concentration(C<sub>max</sub>) of 3-OH-desloratedine produced at arithmetic mean time to maximum plasma concentration (T<sub>max</sub>) of about 4.80 hours post dose, is about 2.0 ng/mL, and an area under the concentration-time curve of desloratedine is about 32.3 ng.hr/mL.
- (58) A method of treating and/or preventing the nasal and non-nasal symptoms of seasonal and perennial allergic rhinitis in a human of 12 years and older in need of such treating and /or preventing which comprises administering to said human about 5.0 mg of desloratadine once a day for about 10 days to produce at an arithmetic mean time to maximum plasma concentration (T<sub>max</sub>) of about 3 hours post dose, an arithmetic mean steady state maximum plasma concentration (C<sub>max</sub>) of desloratadine of about 4 ng/mL, and an area under the concentration-time curve of 56.9 ng.hr/mL of desloratadine.
  - (59) The method of claim 58 wherein the arithmetic mean steady state maximum plasma concentration(C<sub>max</sub>) of 3-OH-desloratedine produced at arithmetic mean time to maximum plasma concentration (T<sub>max</sub>) of about 4.80 hours post dose, is about 2.0 ng/mL, and an area under the concentration-time curve of desloratedine is about 32.3 ng. nr/mL.